Clinical Trial Update: GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety trial of GEN1029 (HexaBody-DR5/DR5) in malignant solid tumors (termina ted; results posted in 2022).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Cancer

Drugs mentioned

• GEN1029 (HexaBody-DR5/DR5)

Snippet

Sponsor: Genmab | Conditions: Colorectal Cancer, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-12